JPRN-UMIN000016078
Completed
未知
Evaluation of the safety and efficacy of low dose transgenic rice containing peptides from Japanese cedar pollen allergens. - Evaluation of the safety and efficacy of low dose transgenic rice containing peptides from Japanese cedar pollen allergens.
The Jikei University, School of Medicine0 sites21 target enrollmentDecember 29, 2014
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- The Jikei University, School of Medicine
- Enrollment
- 21
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) A person who is allergic to Rice or has a history of Rice allergy. 2\) A person who shows Pet/House dust specific IgE antibody valued over Class V, and has pet (dogs and cats). 3\) A person who is imperative to use medicine such as anti\-allergic agent and steroidal chemicals that potentially influence the outcome of evaluation. 4\) A person who underwent an operation that is accompanied to nasal disorder within last 2years, or has nasal disorder such as acute/chronic\-rhinitis, rhinopolypus, hypertronic rhinitis, septal deviation, sinusitis which all are potentially hinder to the outcome of evaluation. 5\) A person who has any disorders under treatment and the condition is unstable that trial investigator has asessed as mismatched participant. 6\) A person who has a history of serious disorder such as diabetes, hepatic disorder, kidney disorder, and cardiac disorder. 7\) A person who takes beta\-blocker in order to treat complecating disorders such as hypertension, and / or cardiac disorder. 8\) A person who takes alpha\-blocker in order to treat complecating disorders such as prostatic hyperplasia. 9\) A person who is complecated by immunodeficiency disorder, cancer, or severe enemia. 10\) A person who is complecated by asthma. 11\) A person who'S pre\-clinical test showed AST(GOT), ALT(GRT), Creatinine or BUN value exceed 1\.5 times the upper limit or normal, or has other laboratory abonormalities that trial investigator has assessed as mismatched participant. 12\) A person who participates in other clinical test at the onset of this test. 13\) A person who is presently breastfeeding, pregnant, or planning/wishing to be a pregnant during a period of this clinical test. 14\) A person whom trial investigator has asessed as mismatched participant.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 4
A clinical trial to study the efficacy and safety of low dose versus standard dose emicizumab prophylaxis in haemophilia A patients.Health Condition 1: D66- Hereditary factor VIII deficiencyCTRI/2024/01/061593Department of Health Research, India
Not yet recruiting
Not Applicable
Assessment of effectiveness and safety of minimal doses of propofol for sedation for MRI in childreHealth Condition 1: G80- Cerebral palsyHealth Condition 2: K00-K95- Diseases of the digestive systemHealth Condition 3: M00-M99- Diseases of the musculoskeletal system and connective tissueHealth Condition 4: G00-G99- Diseases of the nervous systemHealth Condition 5: G40- Epilepsy and recurrent seizuresCTRI/2019/11/022044OKMANYA TILAK MUNICIPAL MEDICAL COLLEGE AND LOKMANYA MUNICIPAL GENERAL HOSPITA
Active, not recruiting
Not Applicable
ow doses of Rituximab in Graves orbitopathyActive moderate to severe Graves OrbitopathyMedDRA version: 14.1Level: PTClassification code 10060742Term: Endocrine ophthalmopathySystem Organ Class: 10015919 - Eye disordersTherapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2012-001980-53-ITFONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO10
Recruiting
Not Applicable
Pilot study on the efficacy and safty of low-dose tocilizumab therapy in elderly RA patientsRheumatoid arthritisJPRN-UMIN000008185Kyushu University Beppu Hospital Department of Metabolism, Hematology and Rheumatic Diseases (DMHRDs)10
Recruiting
Not Applicable
Evaluation of the effect of low-dose lung radiotherapy in the treatment of Covid 19Covid-19 Pneumonia.Pneumonia due to SARS-associated coronavirusJ12.81IRCT20201203049585N2Esfahan University of Medical Sciences36